My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

9.840 +0.040 (+0.41%)
Streaming Delayed Price Updated: 10:11 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr. 
Via Benzinga
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current... 
Via Benzinga
Topics Government
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,... 
Via Benzinga
Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Deep Dive Into Dynavax Technologies Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025. 
Via Benzinga
Dynavax (DVAX) Q2 Revenue Jumps 29%
Via The Motley Fool
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
From Deep Track Capital, LP
Via Business Wire
Glass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
Insights into Dynavax Technologies's Upcoming Earnings
 
Via Benzinga
Deep Track Capital Comments on ISS Recommendation
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
From Deep Track Capital, LP
Via Business Wire
Breaking Down Dynavax Technologies: 5 Analysts Share Their Views
 
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
From Deep Track Capital, LP
Via Business Wire
Where Dynavax Technologies Stands With Analysts
 
Via Benzinga
Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer
From Deep Track Capital, LP
Via Business Wire
Evaluating DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:DVAX): Why DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) is Poised for High Growth. 
Via Chartmill
Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors
From Deep Track Capital, LP
Via Business Wire
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
DVAX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
From Deep Track Capital, LP
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand. 
Via Benzinga
This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript
DVAX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.